Clinical Scorecard: Enhancing Neurostimulation Approaches through Thalamic StereoEEG Analysis

At a Glance

Key Highlights

• Under-utilization of epilepsy surgery persists despite evidence of efficacy in seizure reduction and quality-of-life improvement.
• Responsive neurostimulation (RNS) targeting thalamic nuclei shows substantial seizure reduction and decreased SUDEP incidence.
• Hypothesis-driven thalamic SEEG is critical for identifying optimal neuromodulation targets tailored to individual seizure networks.

Guideline-Based Recommendations

Diagnosis

• Use hypothesis-driven thalamic stereoEEG (SEEG) to identify seizure network nodes and inform neuromodulation strategies.
• Consider bilateral CM implantation in patients with focal-to-bilateral tonic-clonic seizures to confirm thalamic involvement.
• In idiopathic generalized epilepsy, CM-region RNS may be initiated without prior SEEG if diagnosis is clear.

Management

• Implement responsive neurostimulation (RNS) targeting anterior nucleus (ANT), centromedian (CM), or pulvinar thalamic nuclei based on seizure network involvement.
• Consider bilateral CM-region RNS for primary generalized and focal-to-bilateral tonic-clonic epilepsies.
• Use deep brain stimulation (DBS) of ANT in focal drug-resistant epilepsy, acknowledging variable real-world effectiveness.

Monitoring & Follow-up

• Continuously record local field potentials via RNS to detect electrographic seizure signatures and deliver stimulation accordingly.
• Monitor seizure frequency reduction and quality-of-life improvements longitudinally, noting median reductions of 58-82% over years.
• Assess for reduction in sudden unexplained death in epilepsy (SUDEP) risk following neuromodulation therapies.

Risks

• Recognize that traditional resective surgery carries perceived high risk and low odds for permanent seizure freedom in extra-temporal and multifocal epilepsy.
• Be aware that real-world effectiveness of ANT-DBS may be lower than trial data, with some patients experiencing no benefit.
• Consider individual variability in thalamic nucleus involvement to avoid suboptimal targeting and treatment failure.

Patient & Prescribing Data

Patients with drug-resistant epilepsy, including those with unilateral or bilateral seizure networks not amenable to resective surgery

RNS shows median seizure reductions of 58% at 3 years improving to 75% at 9 years; bilateral CM RNS yields 81% median reduction at 1 year; 35% of RNS patients achieve ≥90% seizure reduction; SUDEP incidence decreases by 66% post-RNS and ANT-DBS.

Clinical Best Practices

• Employ hypothesis-driven thalamic SEEG to tailor neuromodulation targets to individual seizure network anatomy and propagation patterns.
• Expand thalamic sampling beyond CM nucleus when initial SEEG indicates lack of involvement to optimize treatment planning.
• Integrate anatomical knowledge of thalamocortical projections (ANT, CM, pulvinar nuclei) to guide electrode placement and stimulation strategies.
• Consider quality-of-life improvements as a key treatment success metric alongside seizure frequency reduction.
• Use chronic recording and stimulation capabilities of RNS to disrupt seizure organization effectively.

References

• RNS Pivotal Trial Data
• Real-world RNS Study
• SUDEP Reduction with RNS and ANT-DBS
• Thalamic Neuromodulation Strategies
• Corticothalamic RNS Outcomes
• Bilateral CM-region RNS Outcomes
• Thalamic SEEG for Network Discovery
• Thalamic Nuclei Engagement in Temporal Lobe Epilepsy
• SANTÉ Trial and MORE Registry Data